The slippery slope of the human gene editing debate
By John Evans,
Oxford University Press Blog
| 09. 22. 2020
The ethical debate about what is now called “human gene editing” (HGE) began sixty years ago. At the time, eugenicist scientists wanted to use new knowledge about the structure of DNA to modify humans—to perfect the human species by making us more healthy, musical, intelligent, and generally virtuous. A consensus later formed that gene editing on individuals to remove disease is acceptable, but nobody should try to change the human species. This is known as the somatic (individual) vs. germline (species) distinction, and it served as a moral limit on HGE for 50 years. A few years ago the news broke that a Chinese scientist had facilitated the creation of children who have been genetically modified so their descendants would also be modified—germline HGE. The germline limit now seems to be gone. Are there any limits left?
The HGE debate, like many bioethical debates, is set up like a slippery slope. At the top is an act universally considered morally virtuous (point A). Stepping on the slope at the top makes the act a little bit further down the slope...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...